VIP is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies. VIP is not fda-approved. orphan drug designation for pulmonary hypertension. fda announced plans to remove from compounding lists. As with any research compound, individual responses vary.
Is VIP Safe?
Safety is the most important consideration with any research compound. VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory with a safety profile established through preclinical research.
Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
What Are the Known Side Effects of VIP?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
These effects are based on preclinical data and community reports at standard dosages of 50-100 mcg per spray or 200 mcg daily inhaled. Higher doses generally increase both the likelihood and severity of side effects.
Are VIP Side Effects Dose-Dependent?
Most reported VIP side effects are dose-dependent — meaning they're more likely at higher doses and less likely at the lower end of the 50-100 mcg per spray or 200 mcg daily inhaled range.
This is why starting at the minimum effective dose and titrating up is the standard approach. With a half-life of 2 minutes (extremely short), any adverse effects will typically resolve within a few half-life periods after discontinuation.
What About Long-Term VIP Use?
Long-term safety data for VIP is limited, as with most research peptides. Standard cycles run ongoing continuous therapy.
VIP is not fda-approved. orphan drug designation for pulmonary hypertension. fda announced plans to remove from compounding lists. Extended use beyond recommended cycles should be approached with caution.
Does VIP Interact With Other Compounds?
Combines with inhaled corticosteroids or bronchodilators for synergistic airway relaxation in asthma/COPD.
When stacking peptides, be aware that combining multiple compounds increases the total side-effect surface area. Monitor closely when introducing any new compound.
How Can You Minimize VIP Side Effects?
Start at the lower end of the dosage range (50-100 mcg per spray or 200 mcg daily inhaled). Use proper reconstitution and injection technique to minimize injection site reactions. Store correctly (lyophilized at -20°C, reconstituted at 2-8°C) to maintain purity.
Source only from vendors with third-party COA testing — contaminated or mislabeled products are a significant source of unexpected adverse effects.
What Is the Bottom Line on VIP Safety?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies. Overall, VIP is considered well-tolerated at standard research doses.
Read our VIP dosage guide for protocols designed to minimize risk.
Complete Guide
VIP : Benefits, Dosage, Side Effects & Research
Related Reading
Calculate Your VIP Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for VIP.
Open Calculator →Research-Grade Sourcing
If you're going to research VIP, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is VIP?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues. It is researched for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What is the recommended VIP dosage?
Common dosages: 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) via intranasal spray or inhalation. Cycle length: ongoing continuous therapy. Half-life: 2 minutes (extremely short). Use our peptide calculator for exact reconstitution math.
What are the side effects of VIP?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Is VIP safe?
VIP has shown a favorable safety profile in research. Not FDA-approved. Orphan drug designation for pulmonary hypertension. FDA announced plans to remove from compounding lists. All research should follow appropriate safety protocols.